

Effect of skeletal muscle area and prognostic nutritional index in periampullary tumors

Efecto del área del músculo esquelético y del índice nutricional pronóstico en los tumores periampulares

Gizem Kilinc-Tuncer^{1*}, Ismail Sert², Korhan Tuncer¹, Orkun Sarioglu³, Degercan Yesilyurt¹, Cem Karaali¹, and Mustafa Emiroglu¹

¹Department of General Surgery, University of Health Sciences, Izmir Tepecik Training and Research Hospital; ²Department of General Surgery, Izmir Egepol Hospital; ³Department of Radiology, Izmir Democracy University, Izmir, Turkey

Abstract

Introduction: The skeletal muscle area (SMA) and prognostic nutritional index (PNI) are both considered as predictive parameters for mortality and morbidity for various type of cancer. In this study, we aimed to identify the effects of pre-operative SMA and PNI values on post-operative mortality and morbidity in patients with periampullary region tumors (PRT). **Methods:** Patients between 2010 and 2020 were retrospectively analyzed and divided into two groups according to SMA and PNI cutoff values. Univariate and multivariate analysis was performed to find potential risk factors. **Results:** The mean age was 65.94 ± 11.242 and 54 (60.6%) of the patients were male. Hypertension was found a reducing factor for morbidity in both univariate and multivariate analysis ($p = 0.039$; $p = 0.045$). Chronic obstructive pulmonary disease and low PNI were found as factors affecting mortality in univariate analysis ($p = 0.046$; $p = 0.014$). However, only low PNI was found as an enhancing factor for mortality in multivariate analysis. **Conclusion:** Although SMA is not a risk factor for post-operative morbidity and mortality, PNI can be considered as a risk factor for mortality in patients with PRT.

Keywords: Periampullary region tumor. Prognostic nutritional index. Skeletal muscle area.

Resumen

Introducción: El área del músculo esquelético (SMA) y el índice nutricional pronóstico (PNI) se consideran parámetros predictivos de mortalidad y morbilidad para varios tipos de cáncer. En este estudio, nuestro objetivo fue identificar los efectos de los valores preoperatorios de SMA y PNI sobre la mortalidad postoperatoria, y morbilidad en pacientes con tumores de la región periampular (PRT). **Métodos:** Los pacientes entre 2010-2020 fueron analizados retrospectivamente y divididos en dos grupos según los valores de corte de SMA y PNI. Se realizaron análisis univariados y multivariados para encontrar posibles factores de riesgo. **Resultados:** La edad media fue de 65.94 ± 11.242 y 54 (60.6%) de los pacientes eran varones. Se encontró que la hipertensión es un factor reductor de la morbilidad tanto en el análisis univariado como en el multivariado ($p = 0.039$; $p = 0.045$). La EPOC y el PNI bajo se encontraron como factores que influyen en la mortalidad en el análisis univariante ($p = 0.046$; $p = 0.014$). Sin embargo, solo el PNI bajo se encontró como un factor potenciador de la mortalidad en el análisis multivariado. **Conclusión:** Aunque la SMA no se consideró un factor de riesgo de morbilidad y mortalidad posoperatorias; La PNI puede considerarse un factor de riesgo de mortalidad en pacientes con PRT.

Palabras clave: Tumor de la región periampular. Índice nutricional pronóstico. Área del músculo esquelético.

*Correspondence:

Gizem Kilinc-Tuncer

E-mail: drgizemkilinc@gmail.com

2444-0507/© 2022 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Date of reception: 02-07-2021

Date of acceptance: 07-01-2022

DOI: 10.24875/CIRUE.M22000559

Cir Cir (Eng). 2023;91(1):71-76

Contents available at PubMed

www.cirugiaycirujanos.com

Introduction

Periampullary region tumors (PRT) include the tumors arising from pancreatic head, ampulla of Vater, duodenum, and distal common bile duct¹. Among these tumors, pancreatic head adenocarcinomas present the worst prognosis with a 5-year overall survival of 20%^{2,3}. Pancreaticoduodenectomy (PD) is considered as the curative resection method for the PRT. However, mortality rates of PD are reported < 5% in many published series, morbidity rates are still remains high from 40% to 50%⁴.

Sarcopenia is defined as loss of skeletal muscle mass, strength and function. It is related to prolonged hospitalization, mortality, adverse metabolic affects, and poor quality of life⁵. There are many different types of methods used for evaluating the quantity and quality of muscle mass such as dual-energy X-ray absorptiometry, bioelectrical impedance analysis, lumbar muscle cross-sectional area by computed tomography (CT), or magnetic resonance imaging. The skeletal muscle area (SMA) is one of the parameters that shows sarcopenia. SMA is measured on the inferior end plate of the L3 vertebra and reflects the sum of the surface areas of all the muscles (i.e., psoas, paraspinal, transversus abdominis, rectus abdominis, quadratus lumborum, and internal and external obliques) in this axial image^{6,7}. Prognostic nutritional index (PNI) is calculated with the formula $10 \times \text{serum albumin level (g/dL)} + 0.005 \times \text{total peripheral lymphocyte count (per mm}^3\text{)}$ from serum albumin level and total lymphocyte count⁸. PNI shows the nutritional status of the patients and it is known as a predictive value of morbidity and mortality in pancreatic cancer⁹. In this study, we aimed to identify the effects of pre-operative SMA and PNI values on post-operative mortality and morbidity in patients with PRT.

Materials and methods

Patients that underwent PD for periampullary region malignant tumors between January 2010 and January 2020 were retrospectively analyzed. Patients' age, gender, comorbidities, localizations of the tumor, histological types of tumor, tumor stages, American Society of Anesthesiology (ASA) scores, total lymphocyte counts, pre-operative levels of albumin, pre-operative PNI, pre-operative SMA, post-operative mortality and morbidity, post-operative hospital stay, and post-operative Clavien Dindo complication scores were defined as

parameters. PNI was calculated with the formula of Onodera according to the laboratory parameters that checked 1 week before the operation. SMA values of patients were measured by retrospective examination of CT scans that taken in the supine position for the tumor staging before the surgery. Patients were divided into two groups for SMA and PNI according to their cutoff values that found in receiver operating characteristic (ROC) curve analysis. Differences between these groups for post-operative hospital stay, mortality, and morbidity were statistically analyzed. Data were statistically analyzed using IBM SPSS Statistics 25.0 package program. As the descriptive statistics, the number of units (n), percent (%), mean $\pm$ standard deviation ($\bar{x} \pm ss$), and Median (Q1-Q3) values was given. Pearson Chi-square and Fisher's exact test were used to evaluate categorical variables. The normal distribution of data's continuous variables were evaluated by Shapiro-Wilk, normality test, and Q-Q graphs. In the comparison of the continuous variables of the two groups, the Independent Sample T test was used for variables with normal distribution, and Mann-Whitney U test for variables that did not fit the normal distribution. Univariate analysis was performed to find potential risk factors and then multivariate analysis was added to identify independent factors. $p < 0.05$ value was considered statistically significant.

Results

A total of 89 patients were detected. The mean age was 65.94 ± 11.242 and 54 (60.6 %) of the patients were male. Eleven (12.4%) patients were diagnosed as distal common bile duct tumor, 42 (47.2%) patients were diagnosed as pancreatic head tumor, and 36 (40.4%) patients were diagnosed as ampulla tumor. Patients' tumor localizations, histological types of tumor, and stages are summarized in table 1 in detail. The mortality and morbidity rate were 19% and 30%, respectively. The most common complication after PD was surgical site infection with 13 patients and the second one was pneumonia with 10 patients. Other complications are summarized in table 2 with details. Patients were divided into two groups according to their cutoff PNI and SMA values that calculated with the ROC analysis. Mean for the PNI in patients who have morbidity and mortality was found 42.52 ± 8.034 and 38.40 ± 7.881 , respectively. Cutoff value for PNI was found 43 and patients were divided into two groups as patients with $PNI \leq 43$ and $PNI > 43$. Morbidity, mortality, hospital stay, and Clavien Dindo complication scores were compared between these

Table 1. Localizations, histological types, and stages of the periapillary region tumors

Histological type and stage	Localization of the tumor, n (%)		
	Distal Choledoc (n = 11) (12.4%)	Pancreatic head (n = 42) (47.2%)	Ampulla of Vater (n = 36) (40.4%)
Histological type of tumor			
Adenocarcinoma	7 (63.6%)	33 (78.6%)	34 (94.4%)
Cholangiocarcinoma	4 (36.4%)	-	-
Intraductal papillary mucinous neoplasia	-	6 (14.35%)	-
Neuroendocrine tumor	-	2 (4.8%)	-
Lymphoma	-	1 (2.4%)	-
Squamous cell cancer	-	-	1 (2.8%)
Gastrointestinal Stromal tumor	-	-	1 (2.8%)
Tumor stages			
Stage 1	2 (18.2%)	5 (11.9%)	12 (33.3%)
Stage 2	6 (54.5%)	18 (42.9%)	3 (8.3%)
Stage 3	3 (27.3%)	10 (23.8%)	19 (52.8%)

Table 2. Post-operative complications in patients underwent PD

Complication	Number of patients (n)
Surgical site infection	13
Pneumonia	10
Acute renal failure	4
Brid ileus	3
Intra-abdominal abscess	2
Evisceration	2
Gastrointestinal bleeding	1
Grade D esophagitis	1
Hepatic abscess	1
Cholangitis	1
Central venous catheter infection	1

PD: pancreaticoduodenectomy.

groups. In patients with low PNI group, mortality and Clavien Dindo complication score were significantly higher ($p = 0.010$, $p = 0.011$) (OR for mortality 0.220, 95% CI 0.065-0.740) (Table 3). SMA values were calculated separately for male and female patients. Mean SMA values for male and female in patients with mortality and morbidity were found as 112 ± 26.453 , 109.83 ± 26.713 , and 94.20 ± 14.412 , 87.55 ± 15.572 , respectively. According to SMA ROC analysis, cutoff values for female and male were 87 and 113, respectively. Patients were divided into two groups and they were compared for morbidity, mortality, hospital stay, and Clavien Dindo complication scores. In both groups,

SMA was not associated with morbidity, mortality, hospital stay, and Clavien Dindo complication score (Table 3). We also categorized patients according to presence of mortality and morbidity. Then, we compared these groups for age, gender, ASA score, lymphocyte count, serum level of albumin, and comorbidities. Hypertension and diabetes mellitus were significantly lower in patients with morbidity ($p = 0.035$ and $p = 0.045$). Serum level of albumin was lower in patients with mortality ($p = 0.011$). Furthermore, chronic obstructive pulmonary disease (COPD) was higher in patients with mortality ($p = 0.040$) (Table 4). Distribution of comorbidity numbers according to Clavien Dindo complication score was also analyzed and we could not find an association between these parameters (Fig. 1). We did univariate and multivariate analysis for factors affecting morbidity and mortality. Hypertension was found a reducing factor for morbidity in both univariate and multivariate analysis ($p = 0.039$ and $p = 0.045$) (odds ratio [95% CI]: 0.350 [0.129-0.946] and 0.303 [0.095-0.973]). COPD and low PNI were found as enhancing factors for mortality in univariate analysis ($p = 0.046$ and $p = 0.014$) (odds ratio [95% CI]: 3.177 [1.019-9.907] and 4.550 [1.351-15.329]). However, only low PNI was found as enhancing factor for mortality in multivariate analysis ($p = 0.024$) (odds ratio [95% CI]: 4.836 [1.233-18.967]) (Table 5).

Discussion

Our study showed that low PNI is an independent prognostic factor for post-operative mortality in patients underwent PD for PRT. On the other hand SMA was not effective on post-operative mortality and

Table 3. Factors associated with low and high PNI and SMA values

Postoperative features	All patients (n = 89)	Low PNI (PNI ≤ 43) (n = 43)	High PNI (PNI > 43) (n = 46)	p value	Low SMA (n = 43)	High SMA (n = 46)	p value
Postoperative length of hospital stay; median (Q1-Q3)	13 (10-20)	13 (9-21)	13 (11-18.5)	0.360*	13 (10-20)	13.5 (10-20.25)	0.490*
Morbidity, n (%)				0.367**			0.630**
Yes	27 (30.3)	15 (34.9)	12 (26.1)		12 (27.9)	15 (32.6)	
No	62 (69.7)	28 (65.1)	34 (73.9)		31 (72.1)	31 (67.4)	
Clavien-Dindo classification, n (%)				0.011**			0.902**
0	45 (50.6)	15 (34.9)	30 (65.2)		23 (53.5)	22 (47.8)	
1	11 (12.4)	8 (18.6)	3 (6.5)		4 (9.3)	7 (15.2)	
2	7 (7.9)	4 (9.3)	3 (6.5)		4 (9.3)	3 (6.5)	
3	9 (10.1)	3 (7.0)	6 (13.0)		4 (9.3)	5 (10.9)	
5	17 (19.1)	13 (30.2)	4 (8.7)		8 (18.6)	9 (19.6)	
Mortality, n (%)				0.010**			0.908**
Yes	17 (19.1)	13 (30.2)	4 (8.7)		8 (18.6)	9 (19.6)	
No	72 (80.9)	30 (69.8)	42 (91.3)		35 (81.4)	37 (80.4)	

Low SMA: SMA≤87 for female or SMA≤113 for male; High SMA: > 87 for female or SMA>113 for male. *Mann-Whitney U test was used for P values. **Pearson Chi-square test was used for P values.

PNI: prognostic nutritional index; SMA: skeletal muscle area.

Table 4. Factors associated with presence of mortality and morbidity

Demographic characteristics of patients	Patients with morbidity (n = 27)	Patients without morbidity	p value	Patients with mortality (n = 17)	Patients without mortality	p value
Age; mean ± standard deviation	66.93 ± 10.63	65.52 ± 11.55	0.589*	68.94 ± 9.73	65.24 ± 11.52	0.224*
Sex			0.771**			0.705**
Male	17 (63%)	37 (59.7%)		11 (64.7%)	43 (59.7%)	
Female	10 (37%)	25 (40.3%)		6 (35.3%)	29 (40.3%)	
ASA score			0.527**			0.098**
ASA I	0	0		0	0	
ASA II	17 (63%)	32 (51.6%)		10 (58.8%)	39 (54.2%)	
ASA III	10 (37%)	29 (46.8%)		6 (35.3%)	33 (45.8%)	
ASA IV	0	1 (1.6%)		1 (5.9%)	0	
Pre-operative total peripheral lymphocyte count (per mm ³); Median (Q1-Q3)	1800 (1300-2400)	1800 (1200-2400)	0.989***	1300 (1100-2200)	1900 (1300-2400)	0.113***
Pre-operative level of albumin (g/dl); Mean ± standard deviation	3.34 ± 0.67	3.44 ± 0.72	0.543*	3.02 ± 0.78	3.5 ± 0.65	0.011*
Comorbidities****						
Hypertension (HT)	7 (25.9%)	31 (50%)	0.035	6 (35.3%)	32 (44.4%)	0.493
Diabetes Mellitus (DM)	5 (18.5%)	25 (40.3%)	0.045	3 (17.6%)	27 (37.5%)	0.119
Coronary Artery Disease	1 (3.7%)	5 (8.1%)	0.663	2 (11.8%)	4 (5.6%)	0.322
Atrial fibrillation	1 (3.7%)	2 (3.2%)	0.909	2 (11.8%)	1 (1.4%)	0.092
Chronic obstructive pulmonary disease	4 (14.8%)	16 (25.8)	0.253	7 (41.2%)	13 (18.1%)	0.040

*Independent sample T test was used for p values. **Pearson Chi-square test was used for p values. ***Mann-Whitney U test was used for p values. ****Fisher's exact test was used for p values.

ASA: American Society of Anesthesiology.


morbidity in these patients. PD is still a complicated surgery with 5% of mortality and 50% of morbidity rate. Factors affecting the post-operative mortality and morbidity are still maintain importance. Importance of

nutritional status in these patients before the operation is well known. Cancer cachexia is a multifactorial syndrome characterized by a sustained loss of skeletal muscle mass and cannot be completely reversed

Table 5. Univariate and multivariate analysis for the factors affecting morbidity and mortality

Variables	Morbidity				Mortality			
	Univariate analyses	p value	Multivariate analyses	p value	Univariate analyses	p value	Multivariate analyses	p value
	Odds ratio (95% CI)		Odds ratio (95% CI)		Odds ratio (95% CI)		Odds ratio (95% CI)	
Age (year)	1.011 (0.971-1.054)	0.585	1.035 (0.980-1.093)	0.219	1.032 (0.981-1.085)	0.223	1.003 (0.943-1.067)	0.930
Male Gender	1.149 (0.453-2.915)	0.771	1.160 (0.381-3.532)	0.793	1.236 (0.411-3.717)	0.705	0.935 (0.263-3.323)	0.917
Hypertension	0.350 (0.129-0.946)	0.039	0.303 (0.095-0.973)	0.045	0.682 (0.227-2.044)	0.494	0.895 (0.242-3.310)	0.868
Diabetes mellitus	0.336 (0.112-1.006)	0.051	0.396 (0.122-1.287)	0.124	0.357 (0.094-1.357)	0.131	0.339 (0.077-1.485)	0.151
Chronic obstructive pulmonary disease	0.500 (0.150-1.668)	0.259	0.284 (0.074-1.092)	0.067	3.177 (1.019-9.907)	0.046	2.892 (0.821-10.185)	0.098
Low SMA	0.800 (0.323-1.983)	0.630	0.633 (0.224-1.785)	0.387	0.940 (0.326-2.708)	0.908	0.810 (0.246-2.668)	0.729
Low PNI	1.518 (0.612-3.767)	0.368	1.327 (0.438-4.023)	0.617	4.550 (1.351-15.329)	0.014	4.836 (1.233-18.967)	0.024

Low SMA: SMA $\leq$ 87 for female or SMA $\leq$ 113 for male; High SMA: > 87 for female or SMA > 113 for male.
CI: confidence interval; PNI: prognostic nutritional index; SMA: skeletal muscle area.

**Figure 1.** Distribution of comorbidity numbers according to Clavien Dindo complication score.

with conventional nutritional support and cause progressive functional impairment¹⁰. Studies showed that complex tumor–host interactions, inflammatory cytokines, hormones, and neuropeptides cause the development of cancer cachexia in patients with pancreatic cancer¹¹. In the literature, SMA value is used for many malignancies as a predictive value for mortality and morbidity¹²⁻¹⁴. Furthermore, it is measured in healthy populations in many studies^{5,15,16}. In the study of Kim et al.⁵, the cutoff values for male and female were found as 119.3 cm² and 74.2 cm². On the other hand

in the study of A. Van der Werf et al.¹⁶, they found the cutoff values in healthy Caucasian population as 134 cm² and 89.2 cm². In our study, we found the cutoff values in patients with PRT as 113 cm² in male and 82 cm² in female which were both lower than healthy population and the median that found in the study of Linder et al.¹⁷. That shows that patients with PRT are inclined sarcopenia than the healthy population. Whereas we could not find any association between the SMA value and increased morbidity and mortality rate. In many studies, SMA is used for predicting the sarcopenia and patients' survival in patients that followed in oncology departments^{14,15,17}. Unfortunately, we could not compare the patients' follow-up SMA values due to having missing data. On the other hand, SMA values in our patients were lower than the healthy population and the patients that underwent PD in the literature. The mortality and morbidity rate in our study was 19% and 30%, respectively. We think that these mortality and morbidity rates in our study are due to being a less experienced hepatopancreatic biliary center with a low annual patient volume and patients with high ASA scores.

PNI was reported as a predictive value for nutritional risk in many studies^{8,9,18,19}. In the study of Hoon Lee et al.⁹, they found the PNI as a predictive parameter for

patients' survival with the 49.5 cutoff in all stages of pancreas cancer. Whereas in another study of Dogan et al., they found that PNI was not a predictive parameter for survival in patients with metastatic pancreatic cancer²⁰. In our study, we found an association between Low PNI and Clavien Dindo complication score and mortality. Furthermore, we found PNI as a risk factor for post-operative mortality in multivariate analysis.

We also analyzed association between patients' age, sex, ASA score, and comorbidities with the mortality and morbidity. In addition, to the literature, hypertension and diabetes mellitus were significantly lower in patients with morbidity. Furthermore, serum level of albumin was significantly lower, and COPD was significantly higher in patients with mortality.

Limitations

The primary limitation of the study is to be a retrospective study. Second, we being a less experienced hepatopancreaticobiliary center with a low annual patient volume caused an incompatible morbidity and mortality rates according to the literature. Third, due to missing data of the patients, we could not analyze the skeletal muscle index which is more predictive parameter for these patients. That may have caused to find the SMA as non-effective parameter for morbidity and mortality.

Conclusion

Although patients have lower SMA values, SMA is not a risk factor for mortality and morbidity in patient that underwent PD for PRT. However, low PNI can be considered as a risk factor for post-operative mortality in these patients.

Funding

No funding was received by any author from any person and/or institution.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References

1. El Nakeeb A, El Sorogy M, Ezzat H, Said R, El Dosoky M, El Gawad M, et al. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: a retrospective study of 5-year survivors. *Hepatobiliary Pancreat Dis Int*. 2018;17:443-9.
2. Ilic M, Ilic I. Epidemiology of pancreatic cancer. *World J Gastroenterol*. 2016;22:9694-705.
3. Dal Molin M, Zhang M, De Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, et al. Very long termsurvival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis. *Clin Cancer Res*. 2015;21:1944-50.
4. Nakeeb AE, Askar W, Atef E, El Hanafy E, Sultan AM, Salah T, et al. Trends and outcomes of pancreaticoduodenectomy for periampullary tumors: a 25-year single-center study of 1000 consecutive cases. *World J Gastroenterol*. 2017;23:7025-36.
5. Kim EH, Kim KW, Shin Y, Lee J, Ko Y, Kim YJ, et al. Reference data and T-scores of lumbar skeletal muscle area and its skeletal muscle indices measured by CT scan in a healthy Korean population. *J Gerontol A Biol Sci Med Sci*. 2021;26:265-71.
6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48:16-31.
7. Park J, Gil JR, Shin Y, Won SE, Huh J, You MW, et al. Reliable and robust method for abdominal muscle mass quantification using CT/MRI: an explorative study in healthy subjects. *PLoS One*. 2019;14:e0222042.
8. Abe A, Kurita K, Hayashi H, Ishihama T, Ueda A. Correlation between prognostic nutritional index and occlusal status in gastric cancer. *Oral Dis*. 2020;26:465-72.
9. Lee SH, Chung MJ, Kim B, Lee HJ, Heo JY, Kim YJ, et al. The significance of the prognostic nutritional index for all stages of pancreatic cancer. *Nutr Cancer*. 2017;69:512-19.
10. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*. 2011;12:489-95.
11. Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? *World J Gastroenterol*. 2014;20:9361-73.
12. Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT-determine sarcopenia in patients with advanced gastric cancer. *PLoS One*. 2018;13:e0202700.
13. Takada K, Yoneshima Y, Tanaka KI, Okamoto I, Shimokawa M, Wakasu S, et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. *J Cancer Res Clin Oncol*. 2020;146:1217-5.
14. Gruber ES, Jomrich G, Tamand D, Gnani M, Schindl M, Sahra K. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. *PLoS One*. 2019;14:e0215915.
15. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. *Sci Rep*. 2018;8:11369.
16. Van der Werf A, Langius JA, De van der Schueren MA, Nurmohamed SA, Van der Pant KA, Blauwhoff-Buskermolen S, et al. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy caucasian population. *Eur J Clin Nutr*. 2018;72:288-96.
17. Linder N, Schaudinn A, Langenhan K, Krenzien F, Hau HM, Benzing C, et al. Power of computed-tomography-defined sarcopenia for prediction of morbidity after pancreaticoduodenectomy. *BMC Med Imaging*. 2019;19:32.
18. Wang L, Wang Y, Zhou Z, Li H. Onodera prognostic nutrition index predicts nutrition risk in gastrointestinal elective operation patients. *Zhonghua Wei Chang Wai Ke Za Zhi*. 2016;9:575-9.
19. Shimizu T, Taniguchi K, Asakuma M, Tomioka A, Inoue Y, Komeda K, et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer. *Anticancer Res*. 2019;39:2169-76.
20. Dogan M, Algin E, Guven ZT, Baykara M, Kos TF, Bal O, et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer? *Curr Med Res Opin*. 2018;34:857-63.